NIKI Company Profile and Key Details

Average 10-day trading volume of 74.69 thousand shares is below the 3-month average of 148.96 thousand, indicating normal recent market interest.

Niki BioSolutions, Inc. has 634.68 thousand shares outstanding. The public float is 535.93 thousand shares, elevated short interest at 1.07% of float. This equals 6.25 thousand shares. The short ratio is 0.19 days. Institutional investors hold 0.86% of the float. Insiders own 47.24%.

Our AI price prediction model suggests that Niki BioSolutions, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -28.81%, with price expected at $3.36 by October 02, 2026, within a range of $3.00 to $3.69 3-Month Outlook: Projected fall of -81.57%, reaching $0.87 by December 17, 2026, with a range of $0.77 to $0.97. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 17, 2027, within a range of $0.00 to $0.11.

Niki BioSolutions, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.14. This means the shares are trading above this model’s fair value.

Valuation shows Niki BioSolutions, Inc. trading at a premium to the broader market with a P/E of -0.25. Our AI forecast model points to short-term weakness (-28.81% over two weeks), a medium-term fall (-81.57% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Niki BioSolutions, Inc. (NASDAQ:NIKI) closed at $4.84 USD, gaining $0.12 (2.54%) from the previous close of $4.72. The stock is currently within 5% of its 52-week low $4.65 and $25.90. With a market capitalization of about $394.15 thousand, Niki BioSolutions, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.17). Key stats such as the average daily volume over the past year has been around 156.33 thousand shares, volume is running light vs its 52-week average. Headquartered in Princeton, NJ, Niki BioSolutions, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chung Yuen Huen, the company employs approximately 1 people and listed since July 20, 2026. Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences.

Niki BioSolutions, Inc. trades at a P/E ratio of -0.25, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.01 suggesting the stock is closer to book value. The P/FCF stands at -0.72, also above market averages.